Through concurrent inhibition of the c-MET/STAT3/AKT signaling networks, HNC018, a novel multi-target small molecule, effectively inhibited the proliferation and oncogenic phenotypes of HNSCC. This evidence concerns the gene MET and head and neck squamous cell carcinoma.